Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
trending now
trending in pharma/biotech
trending in device
pharmagather
advertise
Legal Help
login/register
You are here
Home
»
companies
» Eli Lilly
Eli Lilly
Trajenta Meets Primary Endpoint in Cardiovascular Trial
Trajenta Meets Primary Endpoint in Cardiovascular Trial
CP Wire
Boehringer Ingelheim
Eli Lilly
Trajenta
Flag link:
Trajenta Meets Primary Endpoint in Cardiovascular Trial
Boehringer Ingelheim
Eli Lilly
Trajenta
Flag link:
Eli Lilly, Pfizer celebrate a PhIII success for their blockbuster pain drug contender tanezumab — but questions linger
Eli Lilly, Pfizer celebrate a PhIII success for their blockbuster pain drug contender tanezumab — but questions linger
Endpoints
Eli Lilly
Pfizer
anti-NGF
tanezumab
Flag link:
Lilly Oncology’s strategy? Listen to tough talk from patients—and save data for later
Lilly Oncology’s strategy? Listen to tough talk from patients—and save data for later
Fierce Pharma
Eli Lilly
oncology
patients
Flag link:
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
CP Wire
CHMP
Boehringer Ingelheim
Eli Lilly
EMA
Jardiance
Synjardy
Glyxambi
diabetes
Flag link:
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
Boehringer Ingelheim
Eli Lilly
Jardiance
Synjardy
Glyxambi
Flag link:
Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race
Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race
Endpoints
Eli Lilly
Taltz
Novartis
ankylosing spondylitis
Cosentyx
Flag link:
ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study
ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study
Fierce Pharma
Eli Lilly
Trulicity
diabetes
Novo Nordisk
Victoza
AstraZeneca
Bydureon
ADA
Flag link:
ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis
ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis
Fierce Pharma
ADA
kidney disease
Eli Lilly
Boehringer Ingelheim
Flag link:
5 Biggest Blockbuster Diabetes Drugs of the Future
5 Biggest Blockbuster Diabetes Drugs of the Future
Motley Fool
Eli Lilly
Trulicity
Novo Nordisk
Ozempic
Boehringer Ingelheim
Jardiance
Tresiba
NovoRapid
Flag link:
Merck & Co. could try to acquire Elanco (13.5bn)
Merck & Co. could try to acquire Elanco (13.5bn)
GoinPharma
Merck
animal health
Elanco
M&A
Eli Lilly
Flag link:
Novo reveals more Ozempic data on change in body weight by baseline BMI
Novo reveals more Ozempic data on change in body weight by baseline BMI
Yahoo/Reuters
Novo Nordisk
diabetes
BMI
Ozempic
Eli Lilly
Trulicity
Flag link:
U.S. District Court rules in favor of Lilly's Alimta patent
U.S. District Court rules in favor of Lilly's Alimta patent
Yahoo/Reuters
Eli Lilly
Alimta
Hospira
Dr Reddy's
generics
patents
Flag link:
Lilly's lupus treatment succeeds in mid-stage trial
Lilly's lupus treatment succeeds in mid-stage trial
Reuters
Eli Lilly
lupus
olumiant
baricitinib
clinical trials
Flag link:
Eli Lilly and AstraZeneca Drop PhIII Alzheimer's Candidate – BACE Class May Be Done
Eli Lilly and AstraZeneca Drop PhIII Alzheimer's Candidate – BACE Class May Be Done
CP Wire
Eli Lilly
AstraZeneca
lanabecestat
Alzheimer's disease
BACE inhibitors
Flag link:
Eli Lilly and AstraZeneca Drop PhIII Alzheimer's Candidate – BACE Class May Be Done
Eli Lilly
AstraZeneca
lanabecestat
Alzheimer's disease
Flag link:
Lilly's experimental colitis drug posts positive Phase 2 data
Lilly's experimental colitis drug posts positive Phase 2 data
Biopharma Dive
Eli Lilly
mirikizumab
ulcerative colitis
monoclonal antibodies
Flag link:
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Xconomy
Eli Lilly
Incyte
FDA
rheumatoid arthritis
olumiant
baricitinib
Flag link:
Novo Nordisk's oral diabetes drug beats Jardiance in study
Novo Nordisk's oral diabetes drug beats Jardiance in study
Yahoo/Reuters
diabetes
Novo Nordisk
semaglutide
Jardiance
Eli Lilly
Flag link:
Lilly's cancer business loses its chief just as it's leaning on oncology for growth
Lilly's cancer business loses its chief just as it's leaning on oncology for growth
Fierce Pharma
Eli Lilly
oncology
Flag link:
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »